Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).

MLA

Cocchetti, Carlotta, et al. “Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).” Journal of Sexual Medicine, vol. 18, no. 4, Apr. 2021, pp. 821–29. EBSCOhost, https://doi.org/10.1016/j.jsxm.2021.01.185.

APA

Cocchetti, C., Castellini, G., Iacuaniello, D., Romani, A., Maggi, M., Vignozzi, L., Schreiner, T., den Heijer, M., T’Sjoen, G., & Fisher, A. D. (2021). Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). Journal of Sexual Medicine, 18(4), 821–829. https://doi.org/10.1016/j.jsxm.2021.01.185

Chicago

Cocchetti, Carlotta, Giovanni Castellini, Davide Iacuaniello, Alessia Romani, Mario Maggi, Linda Vignozzi, Thomas Schreiner, Martin den Heijer, Guy T’Sjoen, and Alessandra Daphne Fisher. 2021. “Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).” Journal of Sexual Medicine 18 (4): 821–29. doi:10.1016/j.jsxm.2021.01.185.